BMS‑986490 Solid Tumors Study
Brief Summary
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
Official Title
A Phase 1/2a, Multicenter, Open‑Label, First in Human Study of BMS‑986490 With or Without Bevacizumab in Advanced Solid Tumors (NCT06730750)
Conditions
Advanced Solid Tumors